Probiotics may alleviate symptoms of hay fever, which may be related to bacteria in our gut and nose.

Published Date: 26 Apr 2023

The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.

Read Full News

Latest News

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Obefazimod As An “Exciting” Potential Treatment for Ulcerative Colitis, With Bruce Sands, MD Bruce Sands, MD

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

ANTHEM-UC: Icotrokinra Shows Sustained Efficacy in Moderate-to-Severe Ulcerative Colitis, With Vipul Jairath, MBChB, DPhil Vipul Jaraith, MBChB, DPhil

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Joshua Wechsler, MD, on dupilumab's sustained efficacy in pediatric patients with EoE Joshua Wechsler, MD, MSCI

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

NASPGHAN: Best Practices for Celiac Disease Follow-up with Dale Lee, MD Dale Lee, MD

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

Julie Khlevner, MD, AGAF, Reacts to the FDA Approval of Linaclotide for Pediatric IBS-C Julie Khlevner, MD, AGAF

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

Todays Updates

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial Isabella Ciccone, MPH

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials Noah Stansfield

Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

Todays Updates

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial Isabella Ciccone, MPH

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials Noah Stansfield

Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.

Navigating Opportunities and Obstacles in Gastroparesis, With Ronen Arai, MD Ronen Arai, MD

Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis

Latest News

Fasting-Mimicking Diet Elicits Clinical, Biochemical Response in Mild Crohn’s Disease

Sands explains the potential benefits of obefazimod and reviews findings from ABTECT 1 and ABTECT 2 presented at ACG 2025.

ANTHEM-UC study findings presented at ACG show efficacy, durability and safety of icotrokinra in adults with moderate-to-severe ulcerative colitis.

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

Dale Lee, MD, told HCPLive that regular monitoring and potential psychosocial support are important to help children with celiac disease maintain a gluten-free diet.

Julie Khlevner, MD, AGAF, highlights that FDA approval of linaclotide provides the first pharmacologic therapy for pediatric IBS-C.

News All Time

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Intensive Weight Loss Before Colorectal Cancer Surgery Safe, Feasible

Discussing Safety, Tolerability of Tenapanor in Pediatric IBS-C patients, with Thomas Wallach, MD Thomas Wallach, MD

Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Predicting Teduglutide Treatment Response for Pediatric SBS-IF, With Valeria Cohran, MD

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

H. pylori Geographical Prevalence and NASPGHAN/ESPGHAN Guidelines, With Silvana Bonilla, MD Silvana Bonilla, MD

Multicenter data presented by Silvana Bonilla, MD, at NASPGHAN 2025 highlight regional variation in pediatric H. pylori prevalence and support selective biopsy practices guided by clinical suspicion.

5 Gastroenterology Headlines You Missed in November 2025

5 Gastroenterology Headlines You Missed in November 2025

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

Geographic Disparities in GI Specialist Availability Suggest Limited Access to Care

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AI Tools Fall Short for Dietary Recommendations for Managing IBS

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

Reducing Diagnostic Delays and Improving Follow-Up Care for EoE, With Rosa Yu, MD

The HCPFive: Top News for Healthcare Providers from the Week of 10/05 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clinical trial readouts, in this week's essential news roundup.

Small Intestine Dilation Links to Food-Protein-Induced Enterocolitis Syndrome Chelsie Derman

A recent study reveals that small intestinal dilation significantly contributes to abdominal symptoms in adults with Food-Protein-Induced Enterocolitis Syndrome (FPIES).

LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 Years Abigail Brooks, MA

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

Empirical Donor Selection, 2-Dose Capsule FMT Regimen Improve C Diff Cure Rates Abigail Brooks, MA

Findings from the quality improvement study provide real-world data supporting empirical donor exclusion and multiple-dose capsule FMT to increase CDI cure rates.

FDA Approves Updated Indication for Upadacitinib (Rinvoq) in IBD Abigail Brooks, MA

The decision updates the indication statements for ulcerative colitis and Crohn’s disease to allow use in patients who have received ≥ 1 approved systemic therapy.

HCPLive 5 Stories in Under 5: Week of 10/05 Victoria Johnson

An audio recap of the top 5 stories in healthcare news from the week of 10/5-10/11.

Recommended News For You

Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.

Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma

The Benefits of Exercise for Substance Use Disorders.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs

Launch of the hereditary cancer clinic for precision oncology at Kokilaben Hospital.

Q&A: Researchers discuss identifying potential new protein targets for melanoma therapeutics

Report: Breast cancer mortality continues three decade decline, but steeper increases in incidence for some women

Recommended Articles For You

Targeting Oncology: Expanding Combinatorial Strategies by 2025 

Exploring the Causes and Treatments of Cysts: A Comprehensive Guide 

CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review 

Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

One CAR T-Cell Therapy for Multiple Myeloma Tops Another in Propensity Matched Study

2.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

3.

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

4.

MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA

5.

According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.

1.

Protein S-Palmitoylation in Cancer: A Novel Target in Immunotherapy & Treatment

2.

The Power of Salt Tablets: Unlocking Health Benefits Beyond Sodium

3.

Breast Cancer Secrets: AI-Powered Precision Medicine

4.

What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder

5.

Unlocking the Mystery of Hemoglobin C Trait: A Closer Look at a Rare Blood Disorder

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

3.

Thromboprophylaxis In Medical Settings- An Update

4.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

5.

Efficient Management of First line ALK-rearranged NSCLC - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot